<?xml version="1.0" encoding="UTF-8"?>
<p>A second strategy is to create an ACE-2-like molecule that would bind to the S protein of the coronavirus itself. Again, research in to the 2002 SARS virus demonstrated that soluble ACE-2 proteins blocked the SARS virus from infecting cells in vitro [
 <xref rid="B68-pathogens-09-00231" ref-type="bibr">68</xref>,
 <xref rid="B71-pathogens-09-00231" ref-type="bibr">71</xref>]. The additional benefit to using this strategy lies in the possible prevention of S protein-mediated ACE-2 shedding that has been shown to induce the pulmonary edema characteristic of SARS [
 <xref rid="B72-pathogens-09-00231" ref-type="bibr">72</xref>,
 <xref rid="B73-pathogens-09-00231" ref-type="bibr">73</xref>]. A phase II clinical trial of recombinant ACE-2 in ARDS reported significant modulation of inflammatory proteins, but no significant differences in respiratory parameters [
 <xref rid="B74-pathogens-09-00231" ref-type="bibr">74</xref>]. Further research is necessary to assess if the animal studies will translate to clinical benefit.
</p>
